Conference Reports for NATAP

IAS 2019: Conference on HIV Pathogenesis Treatment and Prevention Mexico City July 21-24 2019 Back

Week 96 Resistance and Adherence Analyses of the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in the AMBER and EMERALD Phase III Trials       Reported by Jules Levin IAS 2019 July 21-24 Mexico City